Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

EVGN stock opened at $0.71 on Thursday. The company has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $0.74. Evogene has a fifty-two week low of $0.45 and a fifty-two week high of $1.44.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. The business had revenue of $0.58 million during the quarter, compared to analysts’ expectations of $1.73 million. During the same period last year, the firm posted ($0.07) earnings per share.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets raised its stake in Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 91,400 shares of the biotechnology company’s stock after buying an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent filing with the SEC. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.